

Memoria Producción Científica 2021

- Vaz MA, Lenza IC, Berron SD, Soberon MCM, Rubio OG, Sarrío RG, Verduguez MTQ, Sarabia R, Benavides M, Rubio AI, Fernandez I, Toribio MG, Alvarez MTT, Tomas A, Horno IM, Sanchez JMS, Munoz SP, **De las Peñas Bataller R**. Elderly glioblastoma patients: Survival analysis according adjuvant therapy and tumor molecular analysis. J. Clin. Oncol. 2021. 39(15): IF:44,544. (1).

- Domenech M, Fabregat C, Mesia C, Esteve A, Berron SD, Pineda E, Sarrío RG, **De las Peñas Bataller R**, Fuster J, Navarro LM, Alonso M, Olier C, Perez P, Berrocal A, Rua MC, Gonzalez AH, Carrato C, Sanz C, Sanchez JMS, Balana C. Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles. J. Clin. Oncol. 2021. 39(15): IF:44,544. (1).

- Lista A, Anguera G, Esteban E, Calvo OF, Garcia I, del Muro XG, Maeso IG, **Lorente Estellés D**, Ortega EM, Pinto A, Puente J, de Velasco G. AUREA study: Atezolizumab (Atezo) combined with split-dose gemcitabine plus cisplatin (s-GC) in locally advanced or metastatic urothelial cancer (LA/mUC): A SOGUG study. J. Clin. Oncol. 2021. 39(15): IF:44,544. (1).

- Lopez F, **Lorente Estellés D**, Perez CL, Ramirez M, Peleteiro P, Gomez A, Henriquez I, Lozano R, Romero N, Alonso T, Molina J, Navarro J, Castano A, Pelari L, Hernandez A, **Morillo Macias V**, Garcia R, **Ferrer Albiach C**, Castro E, Olmos D. Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2021. 39(15): IF:44,544. (1).

- Serna R, **Sánchez Hernández A**, **De Julian Campayo M**, Giron CG, Domine M, Blasco A, Torres JMS, Oramas J, Bosch J, Sala MA, Sereno M, Ortega AL, Velarde L, Hernandez B, Padilla A, Coves J, Lewintre EJ, Molina MA, Romero A, Provencio M. Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients. J. Clin. Oncol. 2021. 39(15): IF:44,544. (1).

- Salgado M, Lenza IC, Berron SDB, Rubio OG, Sarrío RG, Verduguez MTQ, Sarabia R, Diaz J, Rubio AI, Fernandez I, Toribio MG, Alvarez MTT, Tomas A, Horno IM, Sanchez JMS, Munoz SP, Alvarez P, **De las Peñas Bataller R**. Impact of surgery versus other treatment options in recurrent glioblastoma. Analysis of the Spanish Group of Neurooncology Research (GEINO) RETSINE database. J. Clin. Oncol. 2021. 39(15): IF:44,544. (1).

- Pacheco V, Sangil RH, Montes AF, Castellanos PC, Trujillo AC, Rogado J, Antonanzas M, Raga MG, Manzano A, Asensio H, **Lorente Estellés D**, Obispo B, Ostios L, de Ceballos ML, Arbizu MV, Carrasco MG, Cano JM, Piera N, Carmona A, Garcia T, Calderon C. Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study. Ann. Oncol. 2021. 32p. 157-157. IF:32,976. (1).

- Ciruelos EM, Garcia AA, Cortes J, Simon SP, Garate E, Mele M, Montano A, Martinez N, Oliveira M, de la Haba J, Vega E, Martorell AP, De Las Heras BB, De Iburguen BCS, **Martínez de Dueñas E**, Navarro EV, Pascual T, Gonzalez X, Villagrasa P, Prat A. SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype. Ann. Oncol. 2021. 32p. 77-77. IF:32,976. (1).

- Cussac AL, Perez JM, Blanch S, Tolosa P, Borrego MR, Cortes MG, Fernandez A, Urruticoechea A, Galve E, Banuelos JFC, Ponce J, Alonso JL, Capelan M, **Martínez de Dueñas E**, De Las Heras BB, Rojas B, Martos T, Lopez A, Gomez F, Cortes J. Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA. Ann. Oncol. 2021. 32p. 77-77. IF:32,976. (1).

- Manzano JL, Martin J, Fernandez LA, Benitez G, Medina J, Quindos M, Garcia A, Fernandez O, Simo RV, Majem M, Hernandez LB, de Miguel PA, Campos B, Espinosa E, Cerrolaza J, Gil I, **Lorente Estellés D**, Martinez A, Martin E, Cerezuela P. Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901-DESCRIBE-AD). Ann. Oncol. 2021. 32p. 900-901. IF:32,976. (1).

- Martinez A, Majem M, Barlesi F, Costa EC, Chu Q, Monnet I, **Sánchez Hernández A**, Dahkil S, Camidge DR, He P, Soo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Herbst RS. COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Ann. Oncol. 2021. 32p. 1320-1320. IF:32,976. (1).

- **Paredero Pérez I**, Sanchez JG, Rubio S, Montes A, Llorente RM, Aparicio MC, Maicas MDT, Maiques IM, **Lorente Estellés D**. Prognostic value of geriatric screening tools compared to Balducci criteria on deterioration free survival in elderly patients (pts) with early-stage breast cancer (BC). Ann. Oncol. 2021. 32p. 438-438. IF:32,976. (1).

- Paz L, Arriola E, Campelo MRG, Tain MPD, Blanco MCM, Vega A, Leon L, Calderon VG, **Sánchez Hernández A**, Rodriguez J, Majem M, De la Rosa CA, Cabellos RA, Ciriquian JLM, Amezcua V, Perez JLF, Mellen AC, Baez L, Isla D. Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study. Ann. Oncol. 2021. 32p. 1171-1172. IF:32,976. (1).

- Rubio S, Montes A, **Paredero Pérez I**, Mejorada RL, Laorden NR, Castro E, **Sánchez Hernández A**, Olmos D, **Lorente Estellés D**. Impact of docetaxel on quality of life (QoL) in elderly and non-elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts). Ann. Oncol. 2021. 32p. 648-649. IF:32,976. (1).

- Villar MV, Caro RL, Soberon MCM, Ibanez AH, Sarrio RG, Caro NL, Garcia MA, Verduguez TQ, Berron SD, Horno IM, Cabeza MTT, Gallego O, **De las Peñas Bataller R**, Salgado M, Lenza IC, Cunqueiro AJ, Munoz SP, Toribio MG, Santos JD. Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma. Ann. Oncol. 2021. 32p. 517-517. IF:32,976. (1).

- Llombart A, Perez JM, Bellet M, Dalenc F, Gil M, Ruiz M, Gavila J, Sampayo M, Aguirre E, Schmid P, Marme F, Di S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, **Martínez de Dueñas E**, Amillano K, Malfettone A, Cortes J. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer A Randomized Clinical Trial. JAMA Oncol. 2021. 7. (12):p. 1791-1799. IF:31,777. (1).

- **Lorente Estellés D**, Llacer C, Lozano R, de Velasco G, Romero N, Rodrigo M, **Sánchez Iglesias A**, di C, Castro E, **Ferrer Albiach C**, **Sánchez Hernández A**, Olmos D. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer. Eur. Urol. 2021. 80. (5):p. 641-649. IF:20,096. (1).

- **Peris Sifre M**, Lopez JJ, Maestre A, Jimenez D, Muriel A, Bikdeli B, Weinberg I, Ay C, Mazzolai L, Lorenzo A, Monreal M,RIETE I. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism. Eur. Resp. J. 2021. 58. (1):2002723. IF:16,671. (1).

- Garcia J, Benet M, Cordon L, Piqueras M, Garde J, **de Julian Campayo M**, Gonzalez L, **Lorente Estellés D**, Piera N, Gomez MC, Ruiz V, Carretero J, **Sánchez Hernández A**, Juan O, Lahoz A. Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. J. Thorac. Oncol. 2021. 16(4):p. 788-789. IF:15,609. (1).

- Postel S, Planchard D, Antigny M, Sarto JC, Gomez MD, **De las Peñas Bataller R**, Gonzalez M, Viteri S, Perez JP, Texier M, Granados A, Bueno MTM, Camps CJ, Lopez A, Provencio M,Gazzah A, Soria JC, Besse B, Sureda BM, Rosell R. Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial. J. Thorac. Oncol. 2021. 16(4):p. 752-752. IF:15,609. (1).

- Ferrarotto R, Anderson I, Medgyasszay B, Garcia MR, Edenfield W, Feinstein T, Johnson J, Kalmadi S,Lammers P, Purkalne G, **Sánchez Hernández A**, Pritchett Y, Malik RK, Morris SR, Csozsi T. Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression. J. Thorac. Oncol. 2021. 16(1):p. 4-4. IF:15,609. (1).

- Perez JM, Llombart A, Bellet M, Dalenc F, Gil MJG, Borrego MR, Gavila J,Sampayo M, Aguirre E, Schmid P,Marme F, Di S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, **Martínez de Dueñas E**, Caranana V, Amillano K, Malfettone A, Cortes J. Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL). Cancer Res. 2021. 81(4):IF:12,701. (1).

- Lozano R, Salles DC, Sandhu S, Aragon IM, Thorne H, Lopez F, Rubio J, Gutierrez AM, Maldonado L, di T,Sanz A, Prieto JD, Garcia I, Pacheco MI, Garces T, Llacer C, Romero N, Zambrana F, Lopez PP, **Lorente Estellés D**, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur. J. Cancer. 2021. 147. p. 74-83. IF:9,162. (1).

- Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Pare L, Pernas S, Munoz M, Oliveira M, Vidal M, Llombart A, Cortes J, Galvan P, Bermejo B, Martinez N, Lopez R, Morales S, Garau I, Manso L, Alarcon J, **Martínez de Dueñas E**, Villagrasa P, Prat A, Nuciforo P. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. *npj Precis. Oncol.* 2021. 5. (1):23. IF:8,254. (1).

- Conde AJ, Lopez F, Hervas A, **Morillo Macias V**, Mendez A, Puertas MDM, Albarran JV, De Iturriaga AG, Rico M, de la Torre MLV, Ots PMS, Romasanta L, Peidro JP, Ibanez C, Ferrer F, Zapatero A, Anchuelo J, Rodriguez A, **Ferrer Albiach C**. Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 2021. 111(3):p. 59-59. IF:7,038. (1).

- Lozano R, **Lorente Estellés D**, Aragon IM, Romero N, Nombela P, Mateo J, Reid A, Cendon Y, Bianchini D, Llacer C, Sandhu SK, Sharp A, Rescigno P, Garces T, Pacheco MI, Flohr P, Massard C, Lopez PP, Castro E, de Bono JS, Olmos D. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. *Cancers.* 2021. 13. (10):2334. IF:6,639. (1).

- Cattrini C, Espana R, Mennitto A, Bersanelli M, Castro E, Olmos D, **Lorente Estellés D**, Gennari A. Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. *Cancers.* 2021. 13(18):4522. IF:6,639. (1).

- Ots PMS, Ortuno JZ, Fernandez SP, Canellas EM, San Segundo CG, Vargas MC, Caballero B, Albiac MR, Masedo GV, Alvarez B, Villalba SR, Miguelanez TM, Garcia PD, Sancho G, Gomez LG, Tripero J, Oses MRR, Villoslada CI, Rodriguez A, Chust ML, Soler AF, Martin E, **Morillo Macias V**, Sanchez CF, Moya LT, Lopez JF, Sole JM, Verdu MG, Flores MM, Wals A, Hernandez JE. Impact of covid-19 on patients in radiotherapy oncology departments in Spain. *Radiother. Oncol.* 2021. 161p. 148-151. IF:6,280. (1).

- Campos FL, **Lorente Estellés D**, Llacer C, Henriquez I, Peleteiro P, Gomez A, Ramirez M, Alvarez S, Alonso T, Molina J, Vallejo C, Hervas A, Navarro J, Gomez J, **Morillo Macias V**, Lozano R, Romero N, Garcia R, Hernandez A, Pelari L, **Ferrer Albiach C**, Sancho S, Castro E, Olmos D. Local treatment to the primary tumor and PSA changes as prognostic factors in mCRPC. *Radiother. Oncol.* 2021. 161p. 755-756. IF:6,280. (1).

- Campos FL, **Lorente Estellés D**, Perez CL, Gomez A, Henriquez I, Peleteiro P, Ramirez M, Navarro J, Lozano R, Romero N, Gajate P, Ana C, Gomez J, Alvarez S, Molina J, Pelari L, Hernandez A, **Morillo Macias V**, Garcia R, **Ferrer Albiach C**, Castro E, Olmos D. PSA Progression and survival in mCRPC patients treated with abiraterone or enzalutamide. *Radiother. Oncol.* 2021. 161p. 750-751. IF:6,280. (1).

- Provencio M, Majem M, Guirado M, Massuti B, **De las Peñas Bataller R**, Ortega AL, Domine M, Marse R, Sala MA, Paredes A, Moran T, Vazquez S, Coves J, Larriba JLG, Sanchez JM, Vicente D, Farre N, Fornos LF, Zapata I, Franco F, Serna R, Romero A, Isla D. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. *Lung Cancer.* 2021. 153. p. 25-34. IF:5,705. (1).

- Patel M, **Tena García I**, Jha A, Taieb D, Pacak K. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. *Front. Endocrinol.* 2021. 12625312. IF:5,555. (1).

- Gomez D, Jimenez P, Fernandez AM, Castellanos PC, Arbizu MV, Cabanes RM, **Lorente Estellés D**, Ferreira E, Del Rio J, Garcia TG, Carmona A, Calderon C. Impact of Obesity on Quality of Life, Psychological Distress, and Coping on Patients with Colon Cancer. *Oncologist.* 2021. 26. (5):p. 874-882. IF:5,550. (2).

- **Peraire M**, Guinot C, **Villar M**. Sociodemographic and clinical profiles comparison in an acute hospital unit after a decade (2006-2007 vs 2017-2018). *Eur. Psychiat.* 2021. 64p. 370-370. IF:5,361. (1).

- Ferrarotto R, Anderson I, Medgyasszay B, Garcia MR, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, **Sánchez Hernández A**, Pritchett Y, Morris SR, Malik RK, Csozsi T. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. *Cancer Med.* 2021. 10. (17):p. 5748-5756. IF:4,452. (2).

- Blancas I, Olier C ,Conde V, Bayo JL, **Herrero Vicent C**, Zarcos I, Carabantes F, Baena JM, Cruz J, Ruiz M. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer. *Sci Rep.* 2021. 11. (1):4274. IF:4,380. (1).

- Ortega JJ, Lopez R, Martinez A, Carratala S, **Echeverría Gómez I**, Ortega P. Kleine-Levin syndrome, GABA, and glutamate. *J. Clin. Sleep Med.* 2021. 17(3):p. 609-610. IF:4,062. (2).

- Garcia R, Teresa FM, Mercader E, Mitjavila M, Robledo M, **Tena García I**, Alvarez C, Aristegui M, Bella MR, **Ferrer Albiach C**, Hanzu FA. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. *Clin. Transl. Oncol.* 2021. 23. (10):p. 1995-2019. IF:3,405. (3).

- Alvarez YE, **De las Peñas Bataller R**, Altozano JP, Martinez SR, Alvarez AS, Cordellat AB, Vazquez EB, Jaime JC, Escobar IG, Zambrano CB. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). *Clin. Transl. Oncol.* 2021. 23. (5):p. 931-939. IF:3,405. (3).

- Del Alba AG, Mendez MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez E, **Lorente Estellés D**, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). *Clin. Transl. Oncol.* 2021. 23. (5):p. 969-979. IF:3,405. (3).

- Alvarez YE, **De las Peñas Bataller R**, Altozano JP, Martinez SR, Alvarez AS, Cordellat AB, Vazquez EB, Jaime JC, Escobar IG, Zambrano CB. SEOM clinical guidelines for anaemia treatment in cancer patients (2020) (vol 23, pg 931, 2021). *Clin. Transl. Oncol.* 2021. 23(10):p. 2192-2193. IF:3,405. (3).

- Mateu C, Rodriguez M, Gil I, Benito A, Tomas JM, **Haro Cortés G**. The Association between a MAOB Variable Number Tandem Repeat Polymorphism and Cocaine and Opiate Addictions in Polyconsumers. *Brain Sci.* 2021. 11. (10):1265. IF:3,394. (3).

- Gil I, Fuertes A, Benito A, Almodovar I, **Ochoa de Aranda E** , **Haro Cortés G**.. Prepulse Inhibition in Cocaine Addiction and Dual Pathologies. *Brain Sci.* 2021. 11. (2):269. IF:3,394. (3).

- **Villegas Estevez F**, Martinez V, Suso C, Castilla D, Zaragoza I, Garcia A, **Ferrer Albiach C**. Characterizing Breakthrough Cancer Pain Using Ecological Momentary Assessment with a Smartphone App: Feasibility and Clinical Findings. *Int. J. Environ. Res. Public Health*. 2021. 18. (11):5991. IF:3,390. (1).

- **Echeverría Gómez I**, Cotaina M, Jovani A, **Mora Marín R** , **Haro Cortés G**, Benito A. Proposal for the Inclusion of Tobacco Use in Suicide Risk Scales: Results of a Meta-Analysis. *Int. J. Environ. Res. Public Health*. 2021. 18(11):6103. IF:3,390. (1).

- Pomar MDB, **Sorribes Carreras P**, Pinera M, Orenes A, Romero LC, Hernandez N, Usieto M, Mas FP, Beneitez MV, Viveros MM ,Aguilera CN, Alcolea JO. Real-life study of the effectiveness of a high calorie and high protein formula in the maintenance and improvement of nutritional state in patients with an indication of long-term enteral nutrition. *Endocrinol. Diabetes Nutr*. 2021. 68. (1):p. 11-16. IF:1,417. (4).

- **Real López M**, **Peraire M**, **Ramos Vidal C**, Nath D, Hervas A, Cortes X. Involvement of intestinal dysbiosis in the etiopathogenesis and treatment of autism spectrum disorder; a bibliographic review. *Rev. Neurologia*. 2021. 73. (8):p. 282-295. IF:0,870. (4).

- Redondo A, Girones R, **Ruiz Miravet N**, Iglesias M, Mendiola C, Santaballa A, Manzano A, Rubio MJ, Mallol P, Tornamira MV, Jimenez M, Gonzalez A. Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study). *Eur. J. Gynaecol. Oncol*. 2021. 42. (6):p. 1116-1123. IF:0,196. (4).

- **Villaverde Doménech ME**, Molto R, Gonzalez V, **Aracil Kessler JP**, Carda C, Novella E. Optimization of Adipose Tissue Cryopreservation Techniques in a Murine Model. *PRS-GLOB. OPEN*. 2021. 9. (11):e3926. .

- **Barrué García P**, Sanchez M. The emotional experience of nurses in the Home Hospitalization Unit in palliative care: A qualitative exploratory study. *Enferm. Clin*. 2021. 31. (4):p. 211-221. .

- Vicent RH, **Herrero Vicent C**. Evaluation of the impact of caesarean delivery versus vaginal delivery in women with postpartum depression: a review. *Clin. Investig. Ginecol. Obstet*. 2021. 48(4):100684. .